Verve Therapeutics Lawsuit Submission Form

Company: Verve Therapeutics, Inc.

Ticker: (NASDAQ) VERV

Deadline

Passed

Lead Plaintiff Deadline: October 28, 2024

Case Alerts

Every year, thousands of shareholders miss deadlines to receive settlement funds. Make sure you don’t. Sign up for case alerts.

To receive more detailed alerts provide your information below.

Request Case Alerts

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

Allegations

The filed complaint alleges that Verve Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial of VERVE-101, its investigational gene editing medicine, would be halted; (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle delivery system; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.